{'fraction_non_alphanumeric': 0.021447721179624665, 'fraction_numerical': 0.021447721179624665, 'mean_word_length': 5.073170731707317, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Spotlight on the June 10 Issue

One patient out of 4 who receive thrombolytic therapy for stroke is over 80 years of age, and the proportion with cognitive decline in this age category is high. This article shows that the safety profile of thrombolytic therapy is good in the presence of cognitive decline. Ischemic stroke patients with preexisting cognitive impairment should receive recombinant tissue plasminogen activator if eligible.

See p. 2048; Editorial, p. 2044

Three hundred forty-seven participants from the CHARTER cohort were neurocognitively normal or had asymptomatic neurocognitive impairment (ANI) at baseline. Neurocognitive assessments occurred approximately every 6 months. ANI conveyed a 2-fold to 6-fold increase in risk …